Amgen drug patent challenge slices $2B off Alexion's market cap
August 30, 2019 at 11:33 AM EDT
Alexion's finances rely heavily on its rare disease drug Soliris. The drug is the source of 80 percent of Alexion's annual revenue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|